Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2024-12-30 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
关于注销子公司海思科药业控股集团的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from the company 海思科医药集团股份有限公司 regarding the cancellation (注销) of its subsidiary 海思科药业控股集团. It includes details about the subsidiary, the board meeting resolution approving the cancellation, and the impact on the company. The document is short (1204 characters) and focuses on a corporate structural change rather than financial results or detailed reports. It is not an annual or interim report, audit report, or earnings release. It is also not a regulatory certification or voting result. The content fits best with a Regulatory Filing (RNS) as it is a general regulatory announcement about a corporate action that does not fit other specific categories like M&A or capital changes. Therefore, the classification is RNS with high confidence.
2024-12-30 Chinese
关于获得创新药HSK44459片两项新增适应症IND申请《受理通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of an acceptance notice from the National Medical Products Administration for clinical trial applications of a new drug with additional indications. It includes details about the drug, its clinical trial status, and risk warnings. The document is relatively short (1458 characters) and serves as a formal announcement of regulatory progress rather than a detailed financial or management report. It does not contain financial statements, management discussion, or detailed investor presentation content. It is not a report publication announcement since it contains substantive information about the regulatory acceptance. The content fits best under Regulatory Filings (RNS) as it is a general regulatory announcement about clinical trial acceptance and risk disclosure, which does not fit other more specific categories.
2024-12-30 Chinese
关于召开2025年第一次临时股东大会通知的公告
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed announcement regarding the convening of the company's 2025 first extraordinary general meeting of shareholders. It includes information about the meeting date, voting procedures (both in-person and online), registration details, agenda items to be voted on, and proxy voting instructions. There is no financial data, earnings information, or report content included. The document serves as a formal notice to shareholders about the meeting and how to participate, which fits the definition of a Proxy Solicitation & Information Statement (PSI). The document length is 3544 characters, which is consistent with a detailed meeting notice rather than a full report or results announcement.
2024-12-30 Chinese
关于获得产业扶持资金的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (1285 characters) about the company receiving industrial support funds (government subsidies). It details the amount, timing, and accounting treatment of the subsidy, emphasizing it is related to ordinary business activities and will increase profit. There is no detailed financial statement or comprehensive report. The document is an announcement of a capital-related event (receipt of government subsidy) rather than a full financial report or audit. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is best classified as a Capital/Financing Update (CAP) because it informs about a financing-related event (government funding) impacting the company's capital or income. The document is not a regulatory filing or report publication announcement since it contains substantive information about the funding event itself. Confidence is high due to clear content and context.
2024-12-18 Chinese
关于控股股东部分股份质押及解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the pledge and release of shares held by a controlling shareholder of the company. It details the number of shares pledged, the proportion of shares involved, pledge start and end dates, and related information. There is no financial performance data, no discussion of financial results, no management commentary, and no mention of a report being attached or published. The content focuses on share pledging activities by a major shareholder, which fits the category of Major Shareholding Notification (MRQ). The document length is short (2077 characters), and it is clearly a notification about shareholding changes, not a full report or an announcement of a report publication.
2024-12-16 Chinese
关于控股股东及其一致行动人股份变动达1%的公告
Major Shareholding Notification Classification · 100% confidence The document is a detailed announcement regarding changes in shareholding proportions of the controlling shareholder and their concerted parties, specifying share reduction amounts, dates, and related shareholder information. It includes disclosures about shareholding changes reaching or exceeding 1%, details of share reduction plans, and compliance with securities laws. There is no financial performance data, earnings information, or management discussion. The document is a formal notification of significant shareholding changes, fitting the definition of a Major Shareholding Notification (MRQ). The document length is under 5,000 characters and contains detailed shareholding change data, not just a brief announcement or certification, so it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA).
2024-12-08 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.